Close Menu

NEW YORK – Castle Biosciences reported after the close of the market on Monday that its third quarter revenues rose 3 percent year over year.

For the three months ended Sept. 30, the skin cancer diagnostics company reported revenues of $15.2 million, up from $14.8 million a year earlier, and beating the average Wall Street estimate of $15.0 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

European regulators have begun a rolling review of Russia's Sputnik V SARS-CoV-2 vaccine, Reuters reports.

Science reports that Science Foundation Ireland is seeking annual budget increases.

According to the Financial Times, a UK university group is pushing Elsevier to lower its journal fees.

In Nature this week: satellite tracking and genome sequencing combination used to examine migration patterns of peregrine falcons, and more.